70987-78-9

Basic information

• Product Name: (2S)-(+)-Glycidyl tosylate
• Synonyms: (S)-Glycidil Tosylate;(S)-Oxiran-2-ylMethyl 4-Methylbenzenesulfonate;(2S)-2-OxiraneMethanol 2-(4-Methylbenzenesulfonate);(S)-(2,3-Epoxypropan-1-yl) 4-Methylbenzenesulfonate;(S)-Oxiran-2-ylMethyl Toluene-4-sulfonate;(S)-Toluene-4-sulfonic Scid OxiranylMethyl Ester;(2S)-(+)-Glycidyl Tosylate p-Toluenesulfonic Acid (2S)-(+)-Glycidyl Ester;(S)-Glycidyl toluene-4-sulphonate
• CAS NO: 70987-78-9
• Molecular Formula: C₁₀H₁₂O₄S
• Molecular Weight: 228.26
• EINECS: 417-210-7
• Product Categories: Carbohydrates & Derivatives;Sulfur & Selenium Compounds;Phenyls & Phenyl-Het;chiral;CHIRAL COMPOUNDS;Chiral Compound;Phenyls & Phenyl-Het;Aromatics
• Mol File: 70987-78-9.mol
• Article Data: 16

Chemical Properties

• Melting Point: 46-49 °C(lit.)
• Boiling Point: 340.07°C (rough estimate)
• Flash Point: >230 °F
• Appearance: White/Fluffy Powder
• Density: 1.3749 (rough estimate)
• Refractive Index: 1.5400 (estimate)
• Storage Temp.: 2-8°C
• Solubility: Dioxane (Slightly), DMSO (Slightly), Methanol (Slightly)
• Water Solubility: decomposes
• BRN: 3592143
• CAS DataBase Reference: (2S)-(+)-Glycidyl tosylate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-(+)-Glycidyl tosylate(70987-78-9)
• EPA Substance Registry System: (2S)-(+)-Glycidyl tosylate(70987-78-9)

Safety Data

• Hazard Codes: T,N,Xi
• Statements: 45-41-43-51/53-68
• Safety Statements: 53-45-61
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 3
• RTECS: RR0510050
• F: 3-10-21
• HazardClass: 9
• PackingGroup: III
• Hazardous Substances Data: 70987-78-9(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

Uses

Different sources of media describe the Uses of 70987-78-9 differently. You can refer to the following data:
1. (2S)-(+)-Glycidyl tosylate is protected Glycidol, used as an intermediate in the preparation of neurochemicals.
2. Used in the first enantioselective synthesis of (R)- and (S)-4-acetyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrido[3,2-b]oxazines.

InChI:InChI=1/C10H12O4S/c1-8-2-4-10(5-3-8)15(11,12)14-7-9-6-13-9/h2-5,9H,6-7H2,1H3/t9-/m0/s1

Upstream product

• 118712-54-2 glycidyl p-toluenesulfonate 
• 556-52-5 oxiranyl-methanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 57044-25-4 (R)-oxiranemethanol 
• 60827-45-4 (S)-3-chloropropan-1,2-diol 
• 107-06-2 1,2-dichloro-ethane 
• 107-18-6 allyl alcohol 

Downstream Products

• 120019-37-6 3-hexadecyloxy-2R-hydroxypropyl 1-para-toluenesulphonate 
• 119944-30-8 3‐hexadecyloxy‐2R‐hydroxyl propyl‐1‐p‐toluene sulphonate 
• 145987-94-6 (2S)-2-hydroxy-6-(trimethylsilyl)-4-hexynyl tosylate 
• 132059-11-1 R-<1-(2-amino-3-nitrophenoxy)>-2',3'-epoxypropane 
• 132059-13-3 S-<1-(2-amino-3-nitrophenoxy)>-2',3'-epoxypropane 
• 5381-92-0 1,3-diphenylpropan-2-ol 
• 91420-74-5 (S)-(2,3-epoxypropyl)benzene 
• 95043-55-3 (+)-3-(allyloxy)-1,2-epoxypropane 
• 178751-54-7 (S)-2-hydroxy-5-trimethylsilyl-1-p-toluenesulfonyloxy-4-pentyne 
• 101693-40-7 (2S)-(+)-3-[4'-(methyl)-phenoxy]-1,2-epoxypropane 
• 66966-20-9 (S)-3-(2-allyloxyphenoxy)-1,2-epoxypropane 
• 66966-19-6 (R)-1-(2'-allyloxyphenoxy)-2,3-epoxypropane 
• 201543-06-8 Toluene-4-sulfonic acid (S)-3-biphenyl-4-yl-2-hydroxy-propyl ester 
• 129098-55-1 (S)-1,2-epoxy-3-(4-bromophenoxy)propane 

Relevant articles and documents

Novel chiral stationary phases based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin combining cinchona alkaloid moiety

Novel chiral selectors based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin connecting quinine (QN) or quinidine (QD) moiety were synthesized and immobilized on silica gel. Their chromatographic performances were investigated by comparing to the 3,5-dimethyl phenylcarbamoylated β-cyclodextrin (β-CD) chiral stationary phase (CSP) and 9-O-(tert-butylcarbamoyl)-QN-based CSP (QN-AX). Fmoc-protected amino acids, chiral drug cloprostenol (which has been successfully employed in veterinary medicine), and neutral chiral analytes were evaluated on CSPs, and the results showed that the novel CSPs characterized as both enantioseparation capabilities of CD-based CSP and QN/QD-based CSPs have broader application range than β-CD-based CSP or QN/QD-based CSPs. It was found that QN/QD moieties play a dominant role in the overall enantioseparation process of Fmoc-amino acids accompanied by the synergistic effect of β-CD moiety, which lead to the different enantioseparation of β-CD-QN-based CSP and β-CD-QD-based CSP. Furthermore, new CSPs retain extraordinary enantioseparation of cyclodextrin-based CSP for some neutral analytes on normal phase and even exhibit better enantioseparation than the corresponding β-CD-based CSP for certain samples.

Chiral ND - 322, ND - 364 or ND - 364 sulfoxide analogs and its preparation method

The invention relates to a chiral ND-322, ND-364 or ND-364 sulfoxide analog and a preparation method therefor, and belongs to the technical field of pharmaceutical active compound synthesis. The chiral ND-322, ND-364 or ND-364 sulfoxide analog takes chira

Total Synthesis of (+)-Cryptocaryol A Using a Prins Cyclization/Reductive Cleavage Sequence

The total synthesis of (+)-cryptocaryol A was achieved in 20 steps from (R)-glycidol. The key steps were a Prins cyclization/reductive cleavage sequence to construct the C5-C11 polyol fragment, a diastereoselective aldol reaction to control the stereogeni